Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 5Lyxumia

02 2Soliqua

03 1Soliqua/Suliqua

04 2Soliqua/iGlarLixi

PharmaCompass

01

Brand Name : Soliqua/Suliqua

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine, Lixisenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 236

2021 Revenue in Millions : 215

Growth (%) : 10

Sanofi Company Banner

02

Brand Name : Lyxumia

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lixisenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2014 Revenue in Millions : 200.00%

2013 Revenue in Millions :

Growth (%) :

Sanofi Company Banner

03

Brand Name : Soliqua/iGlarLixi

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lixisenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2023 Revenue in Millions : 234

2022 Revenue in Millions : 236

Growth (%) : 1

Sanofi Company Banner

04

Brand Name : Soliqua/iGlarLixi

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine, Lixisenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2024 Revenue in Millions : 235

2023 Revenue in Millions : 234

Growth (%) : 1

Sanofi Company Banner

05

Brand Name : Lyxumia

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lixisenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2015 Revenue in Millions : 30

2014 Revenue in Millions : 42

Growth (%) : 40%

Sanofi Company Banner

06

Brand Name : Lyxumia

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lixisenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2016 Revenue in Millions : 35

2015 Revenue in Millions : 40

Growth (%) : -13

Sanofi Company Banner

07

Brand Name : Lyxumia

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lixisenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2017 Revenue in Millions : 32

2016 Revenue in Millions : 41

Growth (%) : -21

Sanofi Company Banner

08

Brand Name : Soliqua

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine, Lixisenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2017 Revenue in Millions : 32

2016 Revenue in Millions : 0

Growth (%) : New Launch

Sanofi Company Banner

09

Brand Name : Lyxumia

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lixisenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2018 Revenue in Millions : 0

2017 Revenue in Millions : 29

Growth (%) : -100%

Sanofi Company Banner

10

Brand Name : Soliqua

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine, Lixisenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2018 Revenue in Millions : 82

2017 Revenue in Millions : 29

Growth (%) : 181%

Sanofi Company Banner